CTLA4 and neoplasm: In addition to the use of anti-PD-1/PD-L1 or anti-CTLA-4 antibodies, the search of immune inhibitory blockade mechanisms has led to the study of metabolic pathways used by malignant cells to shape tumor microenvironment and to induce immune modulation.